Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Pegargiminase (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Polaris Pharmaceuticals
- 21 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Sep 2018.
- 21 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.
- 18 Aug 2017 Results published in the Cancer.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History